An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.

摘要: Gastric and gastroesophageal adenocarcinoma (GGA) are significant worldwide health problems. With most patients presenting with advanced disease, palliative chemotherapy plays a role in treatment. Results from recent phase III studies of cytotoxic agents combination therapy, such as docetaxel, oxaliplatin, irinotecan, capecitabine, S-1, have been encouraging provide additional therapeutic options. Although these forthcoming regimens allowed for more flexible patient-tailored survival continues to be suboptimal. still its infancy, targeted biotherapy, including inhibitors the vascular endothelial epidermal growth factor receptors, seems promising incorporation into next generation clinical trials will hopefully improve outcomes help advance future treatments. This article reviews current active chemotherapeutic explores novel therapies GGA.